{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:13:32Z","timestamp":1791213212267,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T00:00:00Z","timestamp":1456358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/bjc.2016.44","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T18:45:49Z","timestamp":1456425949000},"page":"801-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival"],"prefix":"10.1038","volume":"114","author":[{"given":"Emilia","family":"Hugdahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Britt","family":"Kalvenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne E","family":"Puntervoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita G","family":"Ladstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars A","family":"Akslen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,25]]},"reference":[{"key":"BFbjc201644_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.0022-202X.2005.23788.x","volume":"125","author":"LA Akslen","year":"2005","unstructured":"Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, Kumar R (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125: 312\u2013317.","journal-title":"J Invest Dermatol"},{"key":"BFbjc201644_CR2","unstructured":"Balch CM, Gershenwald J, Atkins MB (2009) Melanoma of the skin. In AJCC Cancer Staging Manual, Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) 7th edn, pp 325\u2013344."},{"key":"BFbjc201644_CR3","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1016\/j.ejca.2014.06.009","volume":"50","author":"AP Barbour","year":"2014","unstructured":"Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, Lambie D, Burmeister B, Thomas J, Smithers BM, Hayward NK (2014) BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. Eur J Cancer 50: 2668\u20132676.","journal-title":"Eur J Cancer"},{"key":"BFbjc201644_CR4","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/00000658-197011000-00017","volume":"172","author":"A Breslow","year":"1970","unstructured":"Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172: 902\u2013908.","journal-title":"Ann Surg"},{"key":"BFbjc201644_CR5","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1002\/cncr.28306","volume":"119","author":"AD Bucheit","year":"2013","unstructured":"Bucheit AD, Syklawer E, Jakob JA, Bassett RL Jr, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA (2013) Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119: 3821\u20133829.","journal-title":"Cancer"},{"key":"BFbjc201644_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","volume":"122","author":"D Capper","year":"2011","unstructured":"Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, Von Deimling A (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122: 11\u201319.","journal-title":"Acta Neuropathol"},{"key":"BFbjc201644_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/bjc.2014.287","volume":"111","author":"MS Carlino","year":"2014","unstructured":"Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'toole SA, Scolyer RA, Long GV (2014) Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer 111: 292\u2013299.","journal-title":"Br J Cancer"},{"key":"BFbjc201644_CR8","first-page":"705","volume":"29","author":"WH Clark Jr.","year":"1969","unstructured":"Clark WH Jr., From L, Bernardino EA, Mihm MC (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29: 705\u2013727.","journal-title":"Cancer Res"},{"key":"BFbjc201644_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jmoldx.2012.09.001","volume":"15","author":"E Colomba","year":"2013","unstructured":"Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Cote JF, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile JF (2013) Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 15: 94\u2013100.","journal-title":"J Mol Diagn"},{"key":"BFbjc201644_CR10","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","volume":"30","author":"M Colombino","year":"2012","unstructured":"Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Caraco C, Mozzillo N, Ascierto PA, Palmieri G (2012) BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30: 2522\u20132529.","journal-title":"J Clin Oncol"},{"key":"BFbjc201644_CR11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949\u2013954.","journal-title":"Nature"},{"key":"BFbjc201644_CR12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","volume":"24","author":"B Devitt","year":"2011","unstructured":"Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, Dobrovic A, Mcarthur G (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24: 666\u2013672.","journal-title":"Pigment Cell Melanoma Res"},{"key":"BFbjc201644_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/PAI.0000000000000013","volume":"22","author":"L Ehsani","year":"2014","unstructured":"Ehsani L, Cohen C, Fisher KE, Siddiqui MT (2014) BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression. Appl Immunohistochem Mol Morphol 22: 648\u2013651.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"BFbjc201644_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","volume":"17","author":"JA Ellerhorst","year":"2011","unstructured":"Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17: 229\u2013235.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"BFbjc201644_CR15","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/bjd.13521","volume":"172","author":"Z Garcia-Casado","year":"2014","unstructured":"Garcia-Casado Z, Traves V, Banuls J, Niveiro M, Gimeno-Carpio E, Jimenez-Sanchez AI, Moragon M, Onrubia JA, Oliver V, Kumar R, Nagore E (2014) BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma. Br J Dermatol 172 (4): 1128\u20131131.","journal-title":"Br J Dermatol"},{"key":"BFbjc201644_CR16","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/jid.2012.485","volume":"133","author":"V Hofman","year":"2013","unstructured":"Hofman V, Ilie M, Long-Mira E, Giacchero D, Butori C, Dadone B, Selva E, Tanga V, Passeron T, Poissonnet G, Emile JF, Lacour JP, Bahadoran P, Hofman P (2013) Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients. J Invest Dermatol 133: 1378\u20131381.","journal-title":"J Invest Dermatol"},{"key":"BFbjc201644_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2407-14-13","volume":"14","author":"MA Ihle","year":"2014","unstructured":"Ihle MA, Fassunke J, Konig K, Grunewald I, Schlaak M, Kreuzberg N, Tietze L, Schildhaus HU, Buttner R, Merkelbach-Bruse S (2014) Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer 14: 13.","journal-title":"BMC Cancer"},{"key":"BFbjc201644_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/nm0798-844","volume":"4","author":"J Kononen","year":"1998","unstructured":"Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844\u2013847.","journal-title":"Nat Med"},{"key":"BFbjc201644_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jmoldx.2012.08.003","volume":"15","author":"J Lade-Keller","year":"2013","unstructured":"Lade-Keller J, Romer KM, Guldberg P, Riber-Hansen R, Hansen LL, Steiniche T, Hager H, Kristensen LS (2013) Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn 15: 70\u201380.","journal-title":"J Mol Diagn"},{"key":"BFbjc201644_CR20","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/jid.2011.464","volume":"132","author":"RG Ladstein","year":"2012","unstructured":"Ladstein RG, Bachmann IM, Straume O, Akslen LA (2012a) Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma. J Invest Dermatol 132: 1247\u20131252.","journal-title":"J Invest Dermatol"},{"key":"BFbjc201644_CR21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/PAS.0b013e31825a5b45","volume":"36","author":"RG Ladstein","year":"2012","unstructured":"Ladstein RG, Bachmann IM, Straume O, Akslen LA (2012b) Tumor necrosis is a prognostic factor in thick cutaneous melanoma. Am J Surg Pathol 36: 1477\u20131482.","journal-title":"Am J Surg Pathol"},{"key":"BFbjc201644_CR22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/pin.12215","volume":"64","author":"H Liu","year":"2014","unstructured":"Liu H, Li Z, Wang Y, Feng Q, Si L, Cui C, Guo J, Xue W (2014) Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1. Pathol Int 64: 601\u2013606.","journal-title":"Pathol Int"},{"key":"BFbjc201644_CR23","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/sj.jid.5700632","volume":"127","author":"W Liu","year":"2007","unstructured":"Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R, Mason G, Magee J, Angel C, Dobrovic A, Mcarthur GA (2007) Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 127: 900\u2013905.","journal-title":"J Invest Dermatol"},{"key":"BFbjc201644_CR24","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29: 1239\u20131246.","journal-title":"J Clin Oncol"},{"key":"BFbjc201644_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","volume":"37","author":"GV Long","year":"2013","unstructured":"Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, Von Deimling A, Scolyer RA (2013) Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 37: 61\u201365.","journal-title":"Am J Surg Pathol"},{"key":"BFbjc201644_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/jid.2012.283","volume":"133","author":"GJ Mann","year":"2013","unstructured":"Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, Gerega SK, De Silva C, Lai K, Wilmott JS, Synnott M, Hersey P, Kefford RF, Thompson JF, Yang YH, Scolyer RA (2013) BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 133: 509\u2013517.","journal-title":"J Invest Dermatol"},{"key":"BFbjc201644_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjd.13756","volume":"173","author":"VJ Mar","year":"2015","unstructured":"Mar VJ, Liu W, Devitt B, Wong SQ, Dobrovic A, Mcarthur GA, Wolfe R, Kelly JW (2015) The role of BRAF mutations in primary melanoma growth rate and survival. Br J Dermatol 173: 76\u201382.","journal-title":"Br J Dermatol"},{"key":"BFbjc201644_CR28","doi-asserted-by":"publisher","first-page":"e86194","DOI":"10.1371\/journal.pone.0086194","volume":"9","author":"D Meckbach","year":"2014","unstructured":"Meckbach D, Bauer J, Pflugfelder A, Meier F, Busch C, Eigentler TK, Capper D, Von Deimling A, Mittelbronn M, Perner S, Ikenberg K, Hantschke M, Buttner P, Garbe C, Weide B (2014a) Survival according to BRAF-V600 tumor mutations\u2014an analysis of 437 patients with primary melanoma. PLoS One 9: e86194.","journal-title":"PLoS One"},{"key":"BFbjc201644_CR29","doi-asserted-by":"publisher","first-page":"e89218","DOI":"10.1371\/journal.pone.0089218","volume":"9","author":"D Meckbach","year":"2014","unstructured":"Meckbach D, Keim U, Richter S, Leiter U, Eigentler TK, Bauer J, Pflugfelder A, Buttner P, Garbe C, Weide B (2014b) BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy. PLoS One 9: e89218.","journal-title":"PLoS One"},{"key":"BFbjc201644_CR30","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","volume":"18","author":"AM Menzies","year":"2012","unstructured":"Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18: 3242\u20133249.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201644_CR31","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.0022-202X.2004.23468.x","volume":"123","author":"CJ Miller","year":"2004","unstructured":"Miller CJ, Cheung M, Sharma A, Clarke L, Helm K, Mauger D, Robertson GP (2004) Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 123: 990\u2013992.","journal-title":"J Invest Dermatol"},{"key":"BFbjc201644_CR32","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2340\/00015555-2115","volume":"95","author":"D Moreno-Ramirez","year":"2015","unstructured":"Moreno-Ramirez D, Ojeda-Vila T, Rios-Martin JJ, Nieto-Garcia A, Ferrandiz L (2015) Role of age and sex in the diagnosis of early-stage malignant melanoma: a cross-sectional study. Acta Derm Venereol 95: 940\u2013942.","journal-title":"Acta Derm Venereol"},{"key":"BFbjc201644_CR33","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jaad.2013.10.064","volume":"70","author":"E Nagore","year":"2014","unstructured":"Nagore E, Requena C, Traves V, Guillen C, Hayward NK, Whiteman DC, Hacker E (2014) Prognostic value of BRAF mutations in localized cutaneous melanoma. J Am Acad Dermatol 70: 858\u2013862.e851-852.","journal-title":"J Am Acad Dermatol"},{"key":"BFbjc201644_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjd.12492","volume":"170","author":"V Nikolaou","year":"2014","unstructured":"Nikolaou V, Stratigos AJ (2014) Emerging trends in the epidemiology of melanoma. Br J Dermatol 170: 11\u201319.","journal-title":"Br J Dermatol"},{"key":"BFbjc201644_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D","volume":"194","author":"A Nocito","year":"2001","unstructured":"Nocito A, Bubendorf L, Tinner EM, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G (2001) Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194: 349\u2013357.","journal-title":"J Pathol"},{"issue":"5","key":"BFbjc201644_CR36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/j.semdp.2015.02.010","volume":"32","author":"LL Ritterhouse","year":"2015","unstructured":"Ritterhouse LL, Barletta JA (2015) BRAF V600E mutation-specific antibody: a review. Semin Diagn Pathol 32 (5): 400\u2013408.","journal-title":"Semin Diagn Pathol"},{"key":"BFbjc201644_CR37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/bjd.12351","volume":"169","author":"G Safaee Ardekani","year":"2013","unstructured":"Safaee Ardekani G, Jafarnejad SM, Khosravi S, Martinka M, Ho V, Li G (2013) Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Br J Dermatol 169: 320\u2013328.","journal-title":"Br J Dermatol"},{"key":"BFbjc201644_CR38","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.mayocp.2014.02.002","volume":"89","author":"DJ Shah","year":"2014","unstructured":"Shah DJ, Dronca RS (2014) Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc 89: 504\u2013519.","journal-title":"Mayo Clin Proc"},{"key":"BFbjc201644_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","volume":"48","author":"L Si","year":"2012","unstructured":"Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J (2012) Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 48: 94\u2013100.","journal-title":"Eur J Cancer"},{"key":"BFbjc201644_CR40","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ijc.10978","volume":"104","author":"KS Smalley","year":"2003","unstructured":"Smalley KS (2003) A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104: 527\u2013532.","journal-title":"Int J Cancer"},{"key":"BFbjc201644_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/(SICI)1097-0215(19971021)74:5<535::AID-IJC10>3.0.CO;2-5","volume":"74","author":"O Straume","year":"1997","unstructured":"Straume O, Akslen LA (1997) Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 74: 535\u2013539.","journal-title":"Int J Cancer"},{"key":"BFbjc201644_CR42","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0002-9440(10)64922-X","volume":"160","author":"O Straume","year":"2002","unstructured":"Straume O, Akslen LA (2002) Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor\/fibroblast growth factor receptor-1 and ephrin-A1\/EphA2 on melanoma progression. Am J Pathol 160: 1009\u20131019.","journal-title":"Am J Pathol"},{"issue":"2","key":"BFbjc201644_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.humpath.2014.08.018","volume":"46","author":"A Thiel","year":"2014","unstructured":"Thiel A, Moza M, Kytola S, Orpana A, Jahkola T, Hernberg M, Virolainen S, Ristimaki A (2014) Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma. Hum Pathol 46 (2): 169\u2013175.","journal-title":"Hum Pathol"},{"key":"BFbjc201644_CR44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamaoncol.2015.0493","volume":"1","author":"NE Thomas","year":"2015","unstructured":"Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L, Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K (2015) Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma. JAMA Oncol 1: 359\u2013368.","journal-title":"JAMA Oncol"},{"key":"BFbjc201644_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13000-015-0359-0","volume":"10","author":"A Uguen","year":"2015","unstructured":"Uguen A, Talagas M, Costa S, Samaison L, Paule L, Alavi Z, De Braekeleer M, Le Marechal C, Marcorelles P (2015) NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas. Diagn Pathol 10: 121.","journal-title":"Diagn Pathol"},{"key":"BFbjc201644_CR46","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/bjc.2013.29","volume":"108","author":"JS Wilmott","year":"2013","unstructured":"Wilmott JS, Menzies AM, Haydu LE, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, Von Deimling A, Scolyer RA, Long GV (2013) BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br J Cancer 108: 924\u2013931.","journal-title":"Br J Cancer"},{"key":"BFbjc201644_CR47","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s10552-014-0443-x","volume":"25","author":"S Wu","year":"2014","unstructured":"Wu S, Kuo H, Li WQ, Canales AL, Han J, Qureshi AA (2014) Association between BRAF (V600E) and NRAS (Q61R) mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma. Cancer Causes Control 25: 1379\u20131386.","journal-title":"Cancer Causes Control"},{"key":"BFbjc201644_CR48","doi-asserted-by":"publisher","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","volume":"7","author":"M Yancovitz","year":"2012","unstructured":"Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, Pavlick AC, Darvishian F, Christos P, Mazumdar M, Osman I, Polsky D (2012) Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One 7: e29336.","journal-title":"PLoS One"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201644.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201644","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201644.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T12:26:42Z","timestamp":1718368002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,25]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFbjc201644"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.44","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726181090.793517621","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,25]]},"assertion":[{"value":"7 January 2016","order":1,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}